Histogen Reports Second Quarter 2021 Earnings and Provides Business Update
August 11, 2021 16:05 ET
|
Histogen Inc
Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates Initiated Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee HST 004...
Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference
July 29, 2021 16:05 ET
|
Histogen Inc
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021
July 28, 2021 16:05 ET
|
Histogen Inc
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration
June 30, 2021 08:00 ET
|
Histogen Inc
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced the initiation of its Phase 1/2 clinical trial of HST 003 to evaluate the safety and efficacy of human...
Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
June 22, 2021 08:00 ET
|
Histogen Inc
Emricasan Found to be Safe and Well Tolerated with No Serious Adverse Events Patients Completing Treatment with Emricasan had a Complete Resolution of the Symptoms Most Commonly Associated in Mild...
Histogen Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
June 09, 2021 16:01 ET
|
Histogen Inc
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
June 07, 2021 16:05 ET
|
Histogen Inc
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Provides Update on its Development Programs and Pipeline Focus
June 03, 2021 08:00 ET
|
Histogen Inc
Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates HST 003 Trial for Cartilage Regeneration in the Knee Remains On-Track with an Anticipated...
Histogen and Amerimmune Report Publication on Emricasan in COVID-19
May 19, 2021 08:00 ET
|
Histogen Inc
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Reports First Quarter 2021 Earnings and Provides Business Update
May 13, 2021 16:01 ET
|
Histogen Inc
Strengthened Balance Sheet with $20.8 Million of Gross Proceeds from Financing and Warrant Exercises Initiated Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients with Top-Line Data...